Sepracor Inc. licenses the rights to a safer heartburn drug to J&J
Article Abstract:
Johnson and Johnson has received licensing rights for a potentially safer from of the popular heartburn medication Propulsid from Sepracor Inc. in exchange for undisclosed royalties. The drug, which had sales of over $1 billion in 1997, had been referred to federal regulators from the Food and Drug Admnistration as a possible cause of fatal heart-rhythm problems in patients. Propulsid has not been tested on human subjects but animal studies performed by Sepracor have provided promising results.
Comment:
Has given licensing rights for safer form of heartburn medication Propulsid to Johnson & Johnson for undisclosed royalties
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Interneuron's Redux study shows heart effects
Article Abstract:
Interneuron Pharmaceuticals Inc. financed further study of its diet pill Redux and finds that the heart-valve problems that were reported do exist but not to the extent first thought. Meanwhile, the company has already offered to settle all lawsuits relating to the pill for $100 million. The FDA asked for a recall of the drug in September 1997.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The search services want your eyes to find no reason to wander
- Abstracts: GPU Inc. is set to sell 23 power plants to Sithe Energies in $1.67 billion deal
- Abstracts: Northwest affiliate agrees to comply with US order to reinstate service. UAL girds for vote on unionization of ticket agents
- Abstracts: Healtheon struggles in effots to remedy doctors' paper plague. Excite posts loss but revenue gain tops expectations
- Abstracts: Cendant's board agrees to overhaul top options deals. Cendant ends pact to buy American Bankers